TABLE 5.
Immune‐related adverse events
| Type of irAE | MET group (n = 89) | NMET group (n = 377) | p‐value | |||
|---|---|---|---|---|---|---|
| Any grade | Grades 3–5 | Any grade | Grades 3–5 | |||
| Pneumonitis | 11 (12.4%) | 3 (3.4%) | 31 (8.2%) | 10 (2.7%) | 0.220 | |
| Hepatitis | 2 (2.2%) | 2 (2.2%) | 3 (0.8%) | 2 (0.5%) | 0.244 | |
| Enterocolitis | 0 (0%) | 0 | 1 (0.3%) | 1 (0.3%) | 1.000 | |
| Hypothyroidism | 4 (4.5%) | 0 | 17 (4.5%) | 0 | 1.000 | |
| Hematological toxicity a | 0 (0%) | 0 | 1 (0.3%) | 1 (0.3%) | 1.000 | |
| Polyarthritis | 0 (0%) | 0 | 1 (0.3%) | 0 | 1.000 | |
| Total | 17 (19.1%) | 5 (5.6%) | 54 (14.3%) | 14 (3.7%) | 0.382 | |
Abbreviations: irAE, immune‐related adverse event; MET group, concomitant administration of metformin and DPP4 inhibitor (metformin or combination of metformin and DPP4 inhibitor); NMET group, without concomitant administration of metformin and DPP4 inhibitor.
a
neutropenia.